Information Provided By: 
Fly News Breaks for September 28, 2015
ARRY
Sep 28, 2015 | 12:25 EDT
Piper Jaffray analyst Edward Tenthoff said the data that Array BioPharma shared at the ESMO meeting on its MEK-inhibitor binimetinib and BRAF-inhibitor encorafenib have positive read-through to the company's ongoing Phase III COLUMBUS trial, which should report in 2016. At the meeting, Array also reported encouraging Phase Ib data in NRAS-mutant melanoma and Phase II data in BRAF-mutant colorectal cancer, the analyst added. Tenthoff keeps an Overweight rating and $14.50 price target on the stock.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
